Skip to content

Replimune

US · REPL #3130 by market cap Listed 2018
19.07 -0.16 -0.83%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • Rating change
    Wedbush Upgrades Replimune(REPL.US) to Buy Rating, Raises Target Price to $19
    Market Newswire · 2026/8/7
  • Company notice
    Frasers Property: REPL-General Announcement-Issue of S$150 Million Fixed Rate Notes Due 2036 By Frasers Property Treasury Pte. Ltd.
    SGX · 2026/8/28
  • BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/10/29
  • Rating change
    Cantor Fitzgerald Upgrades Replimune(REPL.US) to Buy Rating
    Market Newswire · 2026/7/31
  • Company notice
    AdvancedSystems: REPL-General Announcement-COMMENCEMENT OF LEGAL PROCEEDINGS AGAINST ZICO CAPITAL PTE. LTD. AND APPLICATION FOR INJUNCTION
    SGX · 2026/7/23
  • Wedbush Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $19
    Market Newswire · 2026/10/29
  • Rating change
    Jefferies Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $24
    Market Newswire · 2026/8/17
  • Rating change
    Wedbush Upgrades Replimune(REPL.US) to Buy Rating, Raises Target Price to $12
    Market Newswire · 2026/7/31
  • Rating change
    Piper Sandler Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $14
    Market Newswire · 2026/8/7
  • Rating change
    J.P. Morgan Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $20
    Market Newswire · 2026/8/11
  • Earnings Flash (REPL) Replimune Posts Fiscal Q2 Net Loss $0.54 a Share, Vs. FactSet Est of $0.71 Loss
    MT Newswires · 2026/10/28
  • A Quick Look at Today's Ratings for Replimune(REPL.US), With a Forecast Between $19 to $31
    Market Newswire · 2026/10/29
  • Company notice
    REPL-General Announcement-ADVANCE DIGITAL HEALTHCARE PTE. LTD. SIGNED AN AFFILIATE AGREEMENT WITH EUREKA IN SINGAPORE
    SGX · 2026/10/19
  • Rating change
    J.P. Morgan Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $21
    Market Newswire · 2026/8/26
  • Rating change
    BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $16
    Market Newswire · 2026/7/31
  • Rating change
    Leerink Partners Initiates Replimune(REPL.US) With Buy Rating, Announces Target Price $17
    Market Newswire · 2026/8/4
  • Leerink Partners Initiates Replimune(REPL.US) With Buy Rating, Announces Target Price $31
    Market Newswire · 2026/10/29
  • Company notice
    Sri Trang Gloves: REPL-General Announcement-Reporting Share Repurchase form for Financial Management Purposes No.2 (Revised Date)
    SGX · 2026/9/8
  • Company notice
    Autagco Ltd: REPL-Asset Acquisitions and Disposals-Proposed Acquisition of Yess Ventures Enterprise Sdn. Bhd
    SGX · 2026/11/12
  • Rating change
    BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $20
    Market Newswire · 2026/8/7
  • Company notice
    AdvancedSystems: REPL-General Announcement-COMMENCEMENT OF LEGAL PROCEEDINGS AGAINST ZICO CAPITAL PTE. LTD. AND APPLICATION FOR INJUNCTION
    SGX · 2026/7/23
  • BMO Capital Upgrades Replimune(REPL.US) to Buy Rating, Raises Target Price to $16
    Market Newswire · 2026/6/30
  • Rating change
    Wedbush Downgrades Replimune(REPL.US) to Hold Rating, Cuts Target Price to $9
    Market Newswire · 2026/7/28
  • Company notice
    GuocoLand: REPL-General Announcement-ISSUANCE OF S$110M 2.50% NOTES DUE 2030 UNDER S$3B MMTN PROGRAMME OF GLL IHT PTE. LTD.
    SGX · 2026/6/30
  • J.P. Morgan Upgrades Replimune(REPL.US) to Buy Rating, Raises Target Price to $17
    Market Newswire · 2026/6/27

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:05 · For reference only, not investment advice and not tailored to your situation.

Replimune discussion 0 comments

Add a comment